Posted by TahoeBlue
http://forum.prisonplanet.com/index.php?topic=101338.1200
1997 The CDC agency already has made hybrid viruses with H5N1 samples isolated from patients in Hong Kong in 1997, when the virus first caused human disease. The results of that research have not yet been published,
Feb. 28 1997 - Schering-Plough Mexico Dedicates Pharmaceutical Manufacturing Facility
Before 1998, mainly “classical” H1N1 SI viruses (SIV) were isolated from swine in the United States
August 1998 - A North Carolina herd exhibiting clinical signs of influenza was identified with H3N2 SIV" In 1998, H3N2 viruses emerged and rapidly spread throughout the US swine population (2–4).
These were unique triple reassortant genotype viruses, with hemagglutinin (HA), neuraminidase (NA), and RNA polymerase (PB1) genes of human influenza virus lineage; nucleoprotein (NP), matrix (M), and nonstructural (NS) genes of classical swine virus lineage; and RNA polymerase (PA and PB2) genes of North American avian virus lineage.
Further reassortment between these viruses and classical H1N1 swine viruses led to the emergence of reassortant H1N2 and H1N1 viruses among pigs in the United States
August 1998 - Since that time, isolates from pigs in Texas, Iowa, Minnesota, and Illinois have been typed as H3N2 SIV.
December 1998 - swine influenza virus (SIV) with H3N2 was first identified in Iowa swine
December 1998 - January 1999, a H3N2 subtype of swine influenza virus (SIV) was isolated from clinically affected swine in Iowa (IA), Minnesota, North Carolina (NC), and Texas (TX). A genetic analysis demonstrated that Midwest isolates (IA, MN, TX) and NC isolate were distinct (5).
It suggested the risk for the emergence of new subtype(s) due to reassortment between H1N1 and H3N2.
2001 - 2004 - Mr. Sabatino was Senior Vice President and General Counsel of Baxter International, Inc. from 2001 to 2004
2004 - Mr. Sabatino joined Schering-Plough in 2004 as Executive Vice President and General Counsel. Mr. Sabatino was Senior Vice President and General Counsel of Baxter International, Inc. from 2001 to 2004
2004 - H5N1 outbreak
Jan 14, 2004 - (CDC) will soon launch experiments designed to combine the H5N1 virus and human flu viruses and then see how the resulting hybrids affect animals. For the human virus, investigators will use A (H3N2), the strain that has caused most human flu cases in recent years, according to the CP report
October 2004 - 1,000-head swine farm in Minnesota experienced a severe respiratory disease outbreak in 14-week-old pigs. This suggests that A/Swine/Minnesota/00395/2004 H3N1 influenza virus is a reassortant containing genes from triple-reassortant H3N2 and contemporary H1N1 SIVs.
The recovery of an H3N1 subtype is further evidence of reassortment and antigenic shift in SIVs, justifying ongoing surveillance of animal populations for influenza A viruses that could represent a direct health threat, not only to swine populations, but also to humans
Jan 2005 - H3N2 influenza viruses swept rapidly across Canada. We describe the genetic characterization of reassortant H3N2 viruses from pigs, turkeys, and a swine farm worker in contact with sick pigs during this outbreak.
To our knowledge, this report describes the first isolation of a human/classical swine/avian triple reassortant H3N2 virus from a human.
Jan 01, 2005 First report in Mexico of the prevalence of antibodies to swine influenza virus in humans
Jan 09, 2005 - GSK's Global Launch with Rotarix(TM) starts in Mexico (for rotavirus
July 26, 2005 - Isolation and Genetic Characterization of New Reassortant H3N1 Swine Influenza Virus from Pigs in the Midwestern United States
The recovery of an H3N1 subtype is further evidence of reassortment and antigenic shift in SIVs, justifying ongoing surveillance of animal populations for influenza A viruses that could represent a direct health threat, not only to swine populations, but also to humans
Sep 02, 2005 - GSK purchases Wyeth's vaccine facility - The 90-acre manufacturing site, located in Marietta, Pennsylvania, which Wyeth closed in December, will be used to help develop future vaccines for GlaxoSmithKline
Nov 09, 2005 - DRL to acquire Roche's Mexico business - Reddy's Laboratories has entered into a definitive agreement to acquire Roche's active pharmaceutical ingredient (API) business at the latter's state-of-the-art manufacturing site in Cuernavaca, Mexico.
Aug 2006 - Swine influenza viruses (SIV) naturally infect pigs and can be transmitted to humans. In the pig, genetic reassortment to create novel influenza subtypes by mixing avian, human, and swine influenza viruses is possible.
July 2007 - Efficacy of swine influenza A virus vaccines against an H3N2 virus variant. Vaccination against SIV is now a routine method of respiratory disease control in swine farms because SIV has become 1 of the common causes of respiratory disease in pigs.
Sep 26, 2007 - Roche Inaugurates Facility In Toluca Mexico - The Toluca facility is one of three Roche facilities in the world to produce high-powered drugs
March 2009 - Baxter attempts to spread H5N1 Bird Flu in test vaccines
03/09/2009 - MERCK AND SCHERING-PLOUGH TO MERGE for 41.1 billion
March 12 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY), has announced the signing of an agreement with the Mexican authorities to build a € 100 million facility to manufacture influenza vaccine in Mexico. The announcement was made during a ceremony attended by Felipe Calderon, President of Mexico, and Nicolas Sarkozy, President of France, who was in Mexico City for a State visit
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment